Results 161 to 170 of about 236,269 (292)

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy. [PDF]

A proportion of patients with chronic lymphocytic leukemia achieve a minimal residual disease negative status after therapy. We retrospectively evaluated the impact of minimal residual disease on the outcome of 255 consecutive patients receiving any ...
López Guillermo, Armando, Aymerich Gregorio, Marta, Villamor i Casas, Neus, Rozman, María, Martínez Trillos, Alejandra, Beà Bobet, Sílvia M., Santacruz, Rodrigo, Campo Güerri, Elias, Colomer Pujol, Dolors, Pinyol, Magda, Puente, Xose S., Delgado, Julio (Delgado González), Royo Moreno, Cristina, Giné Soca, Eva, López-Otín, Carlos, López, Cristina, Navarro López, Alba, Cazorla, Maite   +17 more
core  

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients

Frontiers in Oncology, 2023
Angelo Maiolino, Angelo Maiolino, Elaine Sobral Da Costa, Alberto Orfao   +3 more
doaj   +1 more source

Optimal minimal residual disease threshold in pediatric acute myeloid leukemia: A retrospective cohort study based on the TARGET database. [PDF]

PLoS Med
Liao XY, Zheng H, Fang JP, Zhou DH, Qiu KY.   +4 more
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

MINIMAL RESIDUAL DISEASE IN PERIPHERAL BLOOD ASSESSED BY MASS SPECTROMETRY

HemaSphere, 2022
Noemi Puig
doaj   +1 more source

Mass spectrometry-based proteomics and metabolomics in multiple myeloma: a systematic review of prognostic biomarkers and minimal residual disease monitoring. [PDF]

Front Med (Lausanne)
Moursy N, Siraj H, Nasir Z, Tanweer A, Sajid MR.   +4 more
europepmc   +1 more source

Astrocyte heterogeneity in brain metastases

Molecular Oncology, EarlyView.
Astrocytes emerge as pivotal regulators of metastatic colonization, survival, immune remodeling, and therapy response associated with an increasing heterogeneity that requires spatially and longitudinally resolved approaches to uncover regulatory programs and guide context‐specific therapies.
Carolina Hernández‐Oliver, Neibla Priego, Manuel Valiente   +2 more
wiley   +1 more source

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach, Gizem Abaci, Tom Huberty, Axel Lechner, Lukas Käsmann, Jens Ricke, Sophia Stöcklein, Martin Canis, Philipp Baumeister, Marianna Alunni‐Fabbroni   +9 more
wiley   +1 more source

Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group. [PDF]

Clin Hematol Int
Chen W, Cai Z, Chim CS, Chng WJ, Du J, Fu C, Gao W, Hanamura I, Hou J, Huang JS, Ishida T, Li C, Liu A, Ptushkin V, Takezako N, Wong RSM, Yoon DH.   +16 more
europepmc   +1 more source